New quarterly report expected Apr 23, 2026. Report will refresh after results.
G
Gilead Sciences, Inc.
GILD · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
The Market Is Writing a Eulogy for a Business Still Growing
Most investors see Gilead as a pharmaceutical annuity in managed decline — a cash cow being slowly milked into irrelevance. What they're missing is that lenacapavir for HIV prevention isn't a product launch; it's a potential category redefinition that could address hundreds of millions of people with no viable prevention option today, and it's nowhere in the current earnings multiple.
Flowly Score
Apr 16 Close
+73%$138.55
Fair Value
$240.00
72
Strongat $138.55
Business Strength7/10
The HIV franchise is a genuine fortress — switching costs reinforced by clinical risk asymmetry, patent estates on best-in-class building blocks, and a third consecutive platform-level breakthrough in lenacapavir. Capital allocation has been the persistent crack in the armor: a string of premium acquisitions culminating in a large impairment and a now-discontinued magrolimab program suggests the team that built the HIV empire struggles to invest its proceeds with equal discipline.
Financial Resilience8/10
A business where operating cash flow dwarfs reported net income in both boom years and impairment years is a business with real, durable earnings power — the accounting swings are noise, the cash generation is the signal. FCF margins holding in the high-twenties to high-thirties across a pandemic, post-COVID hangover, and multi-billion acquisition cycle is a remarkable demonstration of franchise durability.
Growth & Trajectory6/10
The base business is growing at low-to-mid single digits — respectable for an asset of this size, but not a growth story in the conventional sense. The trajectory question hinges almost entirely on one variable: lenacapavir's commercial ramp in HIV prevention, which could either confirm the 'mature value holding' narrative or shatter it entirely by expanding the addressable market by an order of magnitude.
Valuation8/10at $146.63
A franchise with no major patent expirations until 2036, generating FCF at a mid-teens yield, trading at a multiple that implies the market has already written its terminal-decline verdict — that's the definition of asymmetric pricing. Even under conservative assumptions that ignore lenacapavir's prevention optionality entirely, the intrinsic value calculation skews meaningfully above the current price across every reasonable scenario.
Risk5/10
The concentration in HIV is both the source of the moat and the single largest structural vulnerability — a durable functional cure would not disrupt this business, it would dissolve it. Near-term, the combination of ViiV's cabotegravir competing directly in PrEP, bispecific antibodies threatening CAR-T's individualized manufacturing rationale, and a combined Chairman/CEO seat that reduces board friction exactly when it matters most creates a genuinely elevated risk profile that a clean patent runway and strong cash generation cannot fully offset.
The investment case here is a quality-price mismatch of unusual clarity. The HIV franchise earns returns that most consumer subscription businesses would envy — patients take Biktarvy for life, physicians don't switch stable patients, and no major patents expire until 2036. The market has repriced this business as though its best days are behind it, assigning a multiple that implies a slow harvest rather than a growing franchise. The cash generation proves otherwise: operating cash flow has consistently and materially exceeded accounting profits across every macro environment, a signature of real earnings power rather than accounting engineering. At a mid-teens FCF yield with that franchise quality, the base case already looks mispriced before crediting any optionality. The trajectory question is deceptively simple: this business will look dramatically different in five years depending on one pipeline decision. Lenacapavir's twice-yearly dosing for HIV prevention — already growing explosively from a small base — addresses an adherence problem that daily pills have never solved for broad populations. If regulatory access and commercial execution combine to drive meaningful penetration in high-incidence markets globally, the terminal-decline narrative evaporates. The oncology pivot through Trodelvy and cell therapy is real and growing, but the meaningful earnings driver over the next decade is whether the HIV franchise expands prevention into a much larger installed base or merely maintains its treatment dominance. The single biggest risk is not generic competition, patent cliffs, or even pricing policy — it's functional cure research. CRISPR-based gene editing and broadly neutralizing antibody cocktails are making genuine scientific progress toward a one-time curative intervention. A durable functional cure would not erode Gilead's HIV franchise; it would make it obsolete. This risk operates on a long time horizon but is not imaginary, and it's the scenario that a discounted cash flow model structurally cannot capture. The secondary governance risk — a combined Chairman/CEO seat with a board that has consistently endorsed rather than interrogated expensive acquisition decisions — means there is limited institutional friction when the next large capital commitment enters the discussion.